Related Experiment Videos
Vanadate inhibits agonist binding to D2 dopamine receptor
1Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
Journal of Molecular Neuroscience : MN
|January 1, 1991
Summary
Orthovanadate inhibits D2 dopamine receptor agonist binding, differing from guanine nucleotides. This ATP-dependent effect involves protein phosphorylation, suggesting distinct regulatory mechanisms for dopamine receptors.
Area of Science:
- Neuropharmacology
- Molecular Biology
- Biochemistry
Background:
- The D2 dopamine receptor plays a crucial role in neurotransmission.
- Guanine nucleotides modulate dopamine receptor activity by interacting with G proteins.
- Understanding modulatory mechanisms is key to developing targeted therapeutics.
Purpose of the Study:
- To investigate the effect of orthovanadate on D2 dopamine receptor binding.
- To compare vanadate's mechanism with that of guanine nucleotides.
- To explore the role of ATP and protein phosphorylation in vanadate's action.
Main Methods:
- Radioligand binding assays using D2 dopamine receptor agonists and antagonists.
- Assessment of receptor-G protein interactions.
- Investigation of ATP dependence and protein phosphorylation levels.
Main Results:
- Orthovanadate (micromolar) inhibited high-affinity agonist binding (apomorphine, N-propylnorapomorphine) but not antagonist binding (spiperone, haloperidol).
- Vanadate's effects mimicked guanine nucleotides but did not induce G protein dissociation.
- Vanadate's action was ATP-dependent and correlated with increased protein phosphorylation.
Conclusions:
- Orthovanadate modulates D2 dopamine receptor agonist binding through a mechanism distinct from guanine nucleotides.
- ATP and protein phosphorylation are involved in vanadate's inhibitory effect.
- These findings suggest novel regulatory pathways for dopamine receptor signaling.